Study launched to evaluate the effectiveness of CorPath robotic assistance in performing balloon angioplasty for symptomatic peripheral arterial disease WALTHAM, MA, February 24, 2015 – Corindus ...
The FDA has granted clearance for the CorPath 200 System, a robotic system that assists heart surgeons in restoring blood flow to blocked coronary arteries. Corindus Vascular Robotics, a Natick, MA ...
NATICK, Mass. - Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced that data and acute results from its CorPath PRECISE Trial will be presented during a ...
NEWTON, Mass.--(BUSINESS WIRE)--Corindus, A Siemens Healthineers Company and a leading developer of precision vascular robotics, announced today it presented the results of a first-of-its-kind study ...
There are also other challenges within the procedure including issues of precision and proper stent selection, a phenomenon known as longitudinal geographic miss (LGM), which is caused by sub-optimal ...
Renowned medical journal publishes the successful clinical results of remote PCI procedures using CorPath® GRX Robotic System technology To improve patient outcomes and broaden access to high-level ...
WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today its CorPath® ...
Data demonstrates safety and efficacy of robotic-assisted percutaneous coronary interventions, while enhancing control and radiation protection for interventional cardiologists “This study has the ...
The first-in-human clinical study of the CorPath 200 System performed at the Corbic Research Institute, Envigado, Colombia, was conducted on eight patients to evaluate the safety and technical ...
Corindus Vascular Robotics (Natick, Massachusetts), a developer of precision vascular robotics, said it has been granted a conditional investigational device exemption (IDE) from the FDA to evaluate ...
Corindus Vascular Robotics missed earnings per share expectations by one cent, but Wall Street didn’t seem to mind as shares of the medtech company, which was a 2015 MDEA finalist, soared on Wednesday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results